Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Establish An Initial Therapeutic Range and Safety Data for AI-09 in the Treatment of Glabellar Lines

NCT05565950 is registered in ClinicalTrials.gov with Eirion Therapeutics Inc. as lead sponsor.

NCT NCT05565950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05565950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Establish An Initial Therapeutic Range and Safety Data for AI-09 in the Treatment of Glabellar Lines
Lead sponsor
Eirion Therapeutics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 3, 2022
Completion date
May 22, 2024
Enrollment
96 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines